000283116 001__ 283116
000283116 005__ 20260103103704.0
000283116 0247_ $$2doi$$a10.1002/alz70861_108678
000283116 0247_ $$2ISSN$$a1552-5260
000283116 0247_ $$2ISSN$$a1552-5279
000283116 037__ $$aDZNE-2026-00012
000283116 082__ $$a610
000283116 1001_ $$0P:(DE-2719)9003346$$aGatzen, Julia$$b0$$eFirst author
000283116 1112_ $$aAlzheimer’s Association International Conference$$cToronto$$d2025-07-27 - 2025-07-31$$gAAIC 25$$wCanada
000283116 245__ $$aEpisodic memory network connectivity with aging and Alzheimer’s disease pathology in cognitively unimpaired older adults
000283116 260__ $$c2025
000283116 3367_ $$0PUB:(DE-HGF)1$$2PUB:(DE-HGF)$$aAbstract$$babstract$$mabstract$$s1767354961_32511
000283116 3367_ $$033$$2EndNote$$aConference Paper
000283116 3367_ $$2BibTeX$$aINPROCEEDINGS
000283116 3367_ $$2DRIVER$$aconferenceObject
000283116 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$mjournal
000283116 3367_ $$2DataCite$$aOutput Types/Conference Abstract
000283116 3367_ $$2ORCID$$aOTHER
000283116 520__ $$aBackground:Regions of the medial temporal lobe and posteromedial cortex are crucial for episodic memory and are among the first to be affected by Alzheimer´s disease (AD) pathology. Hyperconnectivity in association with amyloid and tau pathology has been found in preclinical stages of AD, and may be compensatory or detrimental to memory function. Aiming to identify distinct connections displaying aberrant resting-state functional connectivity (rsFC), we hypothesized lower rsFC with higher age in non-pathological aging, and higher rsFC with higher pathology burden, especially in APOE4 carriers.Method:In this preregistered study, we analysed cross-sectional resting-state fMRI data and blood- and PET-markers of amyloid, tau and APOE status from an observational aging cohort (SFB1436). RsFC strength was examined between predefined ROIs. The sample included 187 cognitively unimpaired older adults (71±7years, 92 female, 44 APOE4 carrier). We investigated associations between rsFC, AD pathology burden, and CAG (cognitive age gap) and potential APOE interactions. Multiple regression models and a moderation analysis with rsFC strength were used. An A-T- subcohort was formed to investigate the effect of age on rsFC and to differentiate it from the effect of pathology.Result:We found a significant association between higher blood-based pathology and low rsFC in the right posterior hippocampus to bilateral subgenual medial prefrontal cortex (mPFC). No significant association was observed between rsFC and tau-PET burden, APOE4 status or age (within A-T-subcohort). Additionally, there was no significant effect of pathology on CAG. Furthermore, we found no evidence of rsFC moderating the relationship between pathology and CAG.Conclusion:Our results do not support the initial hypothesis, which predicted hyperconnectivity in distinct brain regions with high pathology. This could be due to relatively low overall pathology burden, consistent with an early preclinical stage of potential disease progression. This interpretation is further supported by the absence of significant associations between pathology or rsFC strength and memory performance. We identified lower rsFC strength in two distinct connections with higher blood-based pathology. These alterations were not observed in the A-T- subcohort, suggesting it to be an early marker differentiating pathological from healthy aging.
000283116 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000283116 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x1
000283116 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x2
000283116 588__ $$aDataset connected to CrossRef, Journals: pub.dzne.de
000283116 7001_ $$0P:(DE-2719)9002356$$aFischer, Larissa$$b1
000283116 7001_ $$0P:(DE-2719)9002133$$aBehrenbruch, Niklas$$b2
000283116 7001_ $$0P:(DE-2719)9002320$$aSchumann-Werner, Beate$$b3
000283116 7001_ $$0P:(DE-2719)9000379$$aSchwarck, Svenja$$b4
000283116 7001_ $$0P:(DE-2719)9002180$$aMolloy, Eóin N.$$b5
000283116 7001_ $$0P:(DE-2719)2812346$$aHochkeppler, Anne$$b6
000283116 7001_ $$0P:(DE-2719)2812734$$aGarcia-Garcia, Berta$$b7
000283116 7001_ $$0P:(DE-2719)9001800$$aBuechel, Anna-Therese$$b8
000283116 7001_ $$0P:(DE-2719)9001517$$aIncesoy, Enise I$$b9
000283116 7001_ $$aRullmann, Michael$$b10
000283116 7001_ $$aPatt, Marianne$$b11
000283116 7001_ $$aSchildan, Andreas$$b12
000283116 7001_ $$aStephens, Andrew W.$$b13
000283116 7001_ $$aBehnisch, Gusalija$$b14
000283116 7001_ $$0P:(DE-2719)9003591$$aMorgado, Barbara$$b15
000283116 7001_ $$aEsselmann, Hermann$$b16
000283116 7001_ $$aSeidenbecher, Constanze I.$$b17
000283116 7001_ $$0P:(DE-2719)2814326$$aSchott, Björn H.$$b18
000283116 7001_ $$aBarthel, Henryk$$b19
000283116 7001_ $$0P:(DE-2719)2814810$$aSabri, Osama$$b20
000283116 7001_ $$0P:(DE-2719)2811317$$aWiltfang, Jens$$b21
000283116 7001_ $$0P:(DE-2719)2812799$$aKreissl, Michael C.$$b22
000283116 7001_ $$0P:(DE-2719)2000005$$aDüzel, Emrah$$b23
000283116 7001_ $$0P:(DE-2719)2811815$$aMaass, Anne$$b24$$eLast author
000283116 773__ $$0PERI:(DE-600)2201940-6$$a10.1002/alz70861_108678$$gVol. 21, no. S7, p. e108678$$nS7$$pe108678$$tAlzheimer's and dementia$$v21$$x1552-5260$$y2025
000283116 8564_ $$uhttps://pub.dzne.de/record/283116/files/DZNE-2026-00012.pdf$$yOpenAccess
000283116 8564_ $$uhttps://pub.dzne.de/record/283116/files/DZNE-2026-00012.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000283116 909CO $$ooai:pub.dzne.de:283116$$pVDB
000283116 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9003346$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000283116 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002356$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000283116 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002133$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000283116 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002320$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000283116 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000379$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000283116 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002180$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000283116 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812346$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000283116 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812734$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000283116 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001800$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000283116 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001517$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b9$$kDZNE
000283116 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9003591$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b15$$kDZNE
000283116 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2814326$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b18$$kDZNE
000283116 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2814810$$aExternal Institute$$b20$$kExtern
000283116 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811317$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b21$$kDZNE
000283116 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812799$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b22$$kDZNE
000283116 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000005$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b23$$kDZNE
000283116 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811815$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b24$$kDZNE
000283116 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000283116 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x1
000283116 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x2
000283116 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2025-01-06$$wger
000283116 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bALZHEIMERS DEMENT : 2022$$d2025-01-06
000283116 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-06
000283116 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-06
000283116 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-06
000283116 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-06
000283116 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-06
000283116 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-06
000283116 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-06
000283116 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bALZHEIMERS DEMENT : 2022$$d2025-01-06
000283116 9201_ $$0I:(DE-2719)1311001$$kAG Maaß$$lMultimodal Neuroimaging$$x0
000283116 9201_ $$0I:(DE-2719)5000006$$kAG Düzel$$lClinical Neurophysiology and Memory$$x1
000283116 9201_ $$0I:(DE-2719)1410006$$kAG Wiltfang$$lMolecular biomarkers for predictive diagnostics of neurodegenerative diseases$$x2
000283116 9201_ $$0I:(DE-2719)1410002$$kAG Fischer$$lEpigenetics and Systems Medicine in Neurodegenerative Diseases$$x3
000283116 9201_ $$0I:(DE-2719)1340016$$kCore MR PET$$lCore MR PET$$x4
000283116 980__ $$aabstract
000283116 980__ $$aVDB
000283116 980__ $$ajournal
000283116 980__ $$aI:(DE-2719)1311001
000283116 980__ $$aI:(DE-2719)5000006
000283116 980__ $$aI:(DE-2719)1410006
000283116 980__ $$aI:(DE-2719)1410002
000283116 980__ $$aI:(DE-2719)1340016
000283116 980__ $$aUNRESTRICTED